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Abstract
Four sequential Aspergillus fumigatus isolates from a patient with chronic granulomatous disease (CGD) eventually failing
azole-echinocandin combination therapy were investigated. The first two isolates (1 and 2) were susceptible to antifungal
azoles, but increased itraconazole, voriconazole and posaconazole MICs were found for the last two isolates (3 and 4).
Microsatellite typing showed that the 4 isolates were isogenic, suggesting that resistance had been acquired during azole
treatment of the patient. An immunocompromised mouse model confirmed that the in vitro resistance corresponded with
treatment failure. Mice challenged with the resistant isolate 4 failed to respond to posaconazole therapy, while those
infected by susceptible isolate 2 responded. Posaconazole-anidulafungin combination therapy was effective in mice
challenged with isolate 4. No mutations were found in the Cyp51A gene of the four isolates. However, expression
experiments of the Cyp51A showed that the expression was increased in the resistant isolates, compared to the azole-
susceptible isolates. The microscopic morphology of the four isolates was similar, but a clear alteration in radial growth and
a significantly reduced growth rate of the resistant isolates on solid and in broth medium was observed compared to
isolates 1 and 2 and to unrelated wild-type controls. In the mouse model the virulence of isolates 3 and 4 was reduced
compared to the susceptible ones and to wild-type controls. For the first time, the acquisition of azole resistance despite
azole-echinocandin combination therapy is described in a CGD patient and the resistance demonstrated to be directly
associated with significant change of virulence.
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Introduction
Aspergillus fumigatus is the Aspergillus species involved in the vast
majority of invasive infections. In contrast to A. terreus, which is
intrinsically resistant to amphotericin B, and certain newly
described species like A. lentulus, which are resistant to multiple
antifungal drugs, A. fumigatus is normally susceptible to all three
antifungal drug classes licensed for the treatment of invasive
aspergillosis [1]. However, clinical failures involving A. fumigatus
isolates with acquired triazole resistance are being increasingly
reported over the recent years [2–7]. Although the impact of
acquired resistance mechanisms on the fungus in terms of
virulence and fitness is not yet understood, evidence is accumu-
lating that isolates with acquired resistance are capable of causing
aspergillus diseases, and that patients with azole resistant
aspergillosis may fail to respond to azole therapy.
Two routes of resistance development have been proposed in A.
fumigatus. The fungus may become resistant through exposure of
the patient to azoles, which has been reported most frequently in
patients with aspergilloma. It has been suggested that the mode of
reproduction of the fungus is important for the phenotypic
expression of azole resistance [8]. In patients with aspergilloma or
other cavitary lesions, the fungus reproduces by asexual sporula-
tion which facilitates transfer of resistance genes to spores and
subsequent offspring [8]. Therefore, patients with cavitary lesions
may be at increased risk of harbouring resistant fungus.
The other route of resistance development is exposure of A.
fumigatus to azole fungicides in the environment [8]. A. fumigatus,
being a saprophytic fungus, may be exposed to azole compounds in
the environment and subsequent become cross-resistant to medical
triazoles [5,9]. This mode of transmission has been suggested in the
Netherlands and A. fumigatus isolates resistant to medical triazoles
were recovered from patients as well as from the environment [5].
The consequence of this mode of transmission is that possibly no
specific risk group can be identified as patients will be randomly
exposed to azole-susceptible and azole-resistant spores.
The most common mechanism of resistance in clinical isolates is
a modification of the target site encoded by the cyp51A gene
leading to reduced binding of the drug [2,3,10,11]. Multiple point
mutations have been reported and, although the phenotype
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multiple azoles is common [2,3,10,12–14]. A specific L98H
alteration in combination with a tandem repeat in the promoter
region (designated TR/L98H) was found to be the dominant
resistance mechanism in Dutch A. fumigatus isolates. It was shown
that both alterations were required for the multi-azole resistant
phenotype [15], and it is considered unlikely that both genomic
changes could arise during azole therapy [4,5,15]. Finally, an
increasing number of azole-resistant isolates are being reported
that have no alterations in the cyp51A gene, indicating that other
yet unknown mechanisms may play a role [3,16].
Patients with chronic granulomatous disease (CGD) might be at
risk for azole-resistant aspergillosis as they may receive life-long
azole antifungal prophylaxis. Azole-resistant aspergillosis has been
reported in two Dutch CGD patients [4]. In both patients the TR/
L98H resistance mechanism was found in the recovered A. fumigatus
isolates indicating that they had acquired the resistant isolate from
the environment [5]. Azole prophylaxis in these patients may give
the resistant spores a selective advantage to germinate and cause
invasive disease compared to azole susceptible spores. Here, we
report for the first time a CGD patient who developed azole
resistance through prolonged combination treatment with azoles
and echinocandin. The resistant phenotype was confirmed in an
animalmodelandthemechanism demonstrated to be differentthan
those previously described.
Materials and Methods
Origin of A. fumigatus isolates
Four isolates of A. fumigatus were obtained over a 2.5 year period
from a 21 year-old patient with CGD at weeks 0, 108, 125, and
127 respectively (designated isolates 1 to 4) (Week 0 being the time
point of isolation of study isolate no 1). Prior to the isolation of the
study isolates the patient had suffered from several bacterial
infections and A. fumigatus had been cultured from sputum 2 years
earlier but this isolate was not stored. Pulmonary imaging showed
mild emphysema with minor bullae in both lungs and progressive
fibroses of the right lung with retraction and displacement of the
mediastinum but no fungus ball containing cavities and no bullae
related inflammation. A. fumigatus was thought to be responsible as
this was the only pathogen repeatedly cultured from respiratory
samples. He was treated with multiple courses of antifungal
therapy. First course consisted of caspofungin monotherapy week
2104 to 2102, caspofungin + voriconazole combination therapy
week 2102 to 297, and voriconazole monotherapy week 297 to
296 with regression of pulmonary symptoms. Half a year later
(week 267) the patient suffered from relapsing infection and due
to the underlying immune defect and the presence of bronciectasis
is was not possible to eliminate the fungus despite the following
antifungal treatment regimens: voriconazole monotherapy week
267 to +12, caspofungin + voriconazole combination therapy
week +12 to +90 followed by caspofungin + posaconazole
combination therapy week +90 to +134.
Based on the radiologic appearance and the clinical course
his disease could be classified as chronic fibrotic pulmonary
aspergillosis [17]. The patient ultimately died from his pulmonary
infection at week 134, autopsy was not performed.
Microbial samples from patients In Denmark are routinely
submitted to the reference laboratory by hospitals. Only accredited
scientists in the reference laboratory have access to these samples.
Strain identification and susceptibility testing
Identification of the fungal isolates was based upon macro-
scopic and microscopic morphology and the ability to grow at
50uC. The identification was confirmed by sequencing of the b-
tubulin gene, as described previously [18]. Genetic relationship of
the four isolates was determined by microsatellite genotyping
[5,19]. Clinical A. fumigatus isolates AZN 8196 and v52–35
originating from patients with proven invasive aspergillosis were
used as controls as well as A. fumigatus reference isolate
NCPF2109.
In vitro susceptibility testing for the azoles was performed using
the EUCAST method [20] and the M38A reference method of
the Clinical Laboratory Standards Institute (CLSI) using a
microbroth dilution format [21]. Susceptibility to caspofungin
and anidulafungin was determined by Etest (AB Biodisk, Solna,
Sweden) using RPMI-1640, 2% glucose agar plates (SSI
Diagnostika, Hillerød,Herlev Hospital, Herlev, Denmark) and 2
days of incubation at 37uC. Aberrant growth in the inhibition
zone was ignored.
Growth kinetic assay
Growth kinetics on solid medium was performed using an
inoculum of 0.5–2.5610
4 CFU/ml and a single spot (5 ml) on
sabouraud and V8 juice agars in triplicates. Plates were incubated
4 days at 37uC and zone diameter measured after 24, 48, 72 and
96 hours. The average diameter was used to determine the radial
growth rate (Kr). Kr was calculated using the linear regression of
the radius versus time using a method described previously [22]. In
vitro growth in fluent medium was determined using a previously
described kinetic system [23,24]. Briefly, 96-wells microtiter plates
were inoculated with 10
4 conidia, agitated for 15 s and incubated
at 37uC inside a plate reader (Rosys Anthos ht3; Anthos Labtec
Instruments GmbH, Salzburg, Austria) for 62 h. The optical
density at 405 nm (OD405) was automatically recorded for each
well every 10 min. The changes in OD over time were used to
generate growth curves. In both assays the reference strain A.
fumigatus NCPF2109 was included as comparator.
Isolation of total RNA
The A. fumigatus isolates were adjusted to an inoculum of
10
7 CFU and incubated 16 hours in 50 ml of Vogel’s minimal
medium at 37uC at 200 rpm in a 5% CO2 humidified chamber.
The grown mycelia were recovered through attachment to 0.8 mm
porous filter units by aspiration. The harvested mycelia were
washed with 0.6 M MgSO4 and briefly air-dried at room
temperature.
Dried mycelia specimens were placed in microcentrifuge tubes
containing 0.6 mm glass beads and immediately frozen in liquid
nitrogen. Homogenization was performed with MagNA Lyser
Instrument. The fungal lysate was collected in extraction buffer
(50 mMTrisHCl pH 8.0,4% aminosalicyclic acid) and 1/5volume
acid-equilibrated phenol chloroform pH 4.7. Phase separation
occurred according to the standard phenol-chloroform procedure:
For optimal RNA yield, precipitation took place upon addition of
2 M LiCl, 1 mM EDTA and overnight incubation at 4uC. The
precipitated RNA was centrifuged at 15000 x g at 4uC for 30 min,
the supernatant was removed and the RNA pellet was collected in
300 ml of resuspension buffer (40 mM TrisHCl pH 7.5, 20 mM
sodium acetate, 5 mM EDTA, 1% SDS). RNA samples were
further dissolved at 37uC for 5 min and with an additional
centrifuging for 5 min at 15000 x g remained debris were pelleted.
Thesupernatant was transferred toacleantubeand1/10volumeof
3 M sodium acetate pH 5.2 and 2.5 vol. of absolute alcohol was
added. Samples were incubated at 4uC for 30 min and centrifuged
at 15000 x g for 30 min at 4uC. The supernatant was removed and
the pellet washed with 70% ethanol. RNA pellet was air-dried and
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in the presence of 1% diethyl pyrocarbonate).
RT-PCR for Cyp51A expression
The concentration and purity of the isolated total RNA were
determined using a NanoDropND-1000 Spectrophotometer(Thermo
scientific). First-strand cDNA synthesis was performed using 1 mgo f
RNA in the presence of 60 mM random hexamer primers.
Thermocycling conditions were 10 min at room temperature;
60 min at 50uC and 5 min at 85uC. Cyp51A expression levels were
determined by real time PCR using the LC480 instrument and the
probes master kit (Roche applied Science). Thermocycling
conditions were: 95xuC for 5 sec; and 50 cycles: 95xuC for 15 sec;
60uC for 45 sec and finally 1 time 40uC 30 sec. The sequences of
primers used in the RT PCR were as follows: Cyp51A forward
59-TCCTGCTCCTTAGTAGCCTGGTT -39; CYP51A reverse
59-GTGCTCCTTGCTTCACCTG -39 and probe 6 -FAM-
AGTGACAGCCCTCAGCGACGAA-BBQ. Actin was amplified
by forward primer 59-ATTGCTCCTCCTGAGCGTAAATAC-
39, reverse primer 59-GAAGGACCGCTCTCGTCGTAC-39
and probe 6-FAM-TCTGGCCTCTCTGTCCACCTTCCA-
BBQ. Experimental samples were run in duplicate. Thus, all
isolates were cultured twice, from each culture two separate cDNA
amplifications were performed. In total four samples for each isolate
were run by RT-PCR for cyp51A and Actin expression levels. The
change in gene expression was determined using the ratio cyp51A/
Actin. For each sample, a control containing only RNA was
included. The background level detected for these controls was
deducted from the corresponding samples.
Immunosuppressed haematogenous invasive
aspergillosis mouse model
The animal studies were conducted in accordance with the
recommendations of the European community (Directive 86/609/
EEC, 24 November 1986). All animal procedures were approved
by the Danish Animal Experimentation Committee under the
Ministry of Justice (number 2004/561-835). NMRI mice (weight
26–30 g, Harlan Scandinavia, Allerød, Denmark) were used
throughout the study and immunosuppression was obtained
through intraperitoneal administration of 200 mg/kg cyclophos-
phamide, at day 23 prior to inoculation and 100 mg/kg at day 0
(day of inoculation). Mice were challenged intravenously in
volumes of 200 ml via a 25-gauge syringe.
Virulence studies
A total of 30 NMRI mice, 5 isolates (the four different clinical
isolates and a reference isolate (A. fumigatus NCPF2109)), 3 inocula
per isolate, and 2 mice per inoculum was used. Thus a total of six
mice were challenged with each isolate, two of which received a
high inoculum (5610
4 CFU/ml), two an intermediate inoculum
(10
4 CFU/ml) and two a low inoculum (2610
3 CFU/ml).
In vivo drug efficacy
A total of 121 NMRI mice (weight 26–30 g, Harlan
Scandinavia, Allerød, Denmark) were immunosuppressed as
described above. Eighty-one mice in groups of 6–15 were
challenged on day 0 intravenously with conidia suspensions
containing 1610
5 CFU A. fumigatus isolate 4, with an azole
resistant phenotype, and 40 mice were infected with 1610
4 CFU/
ml of the A. fumigatus isolate 2, with an azole susceptible phenotype
in two separate experiments. A 10-fold difference in inoculum size
between the S and the R isolate was chosen based upon the
virulence studies in order to obtain similar mortality in the control
groups. Mice were treated once daily on days 1–4 (Monday to
Friday) and 7–10 (Monday to Thursday) with anidulafungin at a
dose of 12 mg/kg intraperitoneally (i.p.), 20 mg/kg posaconazole
p.o., a combination of the two antifungal drugs, or with glucose
i.p. (control mice). Six mice per treatment group were sacrificed on
days 4 and 8 and surviving mice were sacrificed on day 11.
Kidneys were removed aseptically and stored at 280uC for
subsequent CFU and quantitative PCR.
Determination of fungal burden
Left and right kidney from each animal were homogenized
using a Tissue Lyser (Qiagen, TissueLyser Type mm 301), UV
radiated 2 metal beats (3 mm), and 30 HZ in 2 min. 100 mlo f1 0
fold dilutions (range undiluted – 1:1000) of the tissue homogenate
was used to inoculate Sabouraud agar and colonies were counted
at day 2 for CFU determination.
Tissue samples were transferred to MagNA Lyser Green beads
tubes (Roche Applied Science). TE buffer was added and
homogenization was performed for 20 sec at 6500 rpm by using
the MagNA Lyser instrument. Supernatant was used for DNA
isolation by using the automated MagNA Pure system and the
MagNA Pure LC Total Nucleic Acid Isolation Kit according to
manufacturers protocol (Roche Applied Science). PhHV was added
to all samples as an internal isolation control. Concentration of total
Table 1. Susceptibility results obtained by CLSI/EUCAST microdilution (azoles) or by Etest (echinocandins) for four sequential
isolates obtained from a CGD patient over a 127 week period.
Isolate no.
Week of
collection MIC (mg/ml)
Itraconazole Voriconazole Posaconazole Anidulafungin* Caspofungin*
1 0 0.125/0.5 0.5/1 0.016/0.125 0.004 0.064
2 108 0.25/0.5 0.5/1 0.031/0.125 0.004 0.064
3 125 .16/.44 / .4 0.25/0.5 0.004 0.064
4 127 .16/.44 / .4 0.25/1 0.004 0.125
Controls
NCPF2109 NA 0.063/0.5 0.125/1 ,0.016/0.125 0.004 0.064
TR/L98H NA .16/.48 / .4 0.5/0.5 ND 0.25
*MICs are rounded to nearest upper two fold dilution value for the Etest endpoints.
NA: not applicable, ND: not done
doi:10.1371/journal.pone.0010080.t001
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Spectrophotometer (Thermo scientific). Aspergillus loads were deter-
mined by real time PCR using the LC480 instrument and the probes
master kit (Roche applied Science). Thermocycling conditions were:
95xuC for 5 sec; and 50 cycles: 95xuC for 15 sec; 60uCfo r4 5s e ca n d
finally 1 time 40uC 30 sec. The 28S region of Aspergillus sp.
w a sd e t e c t e db yu s i n gp r i m e r sF5 9-TCCTGCTCCTTAG-
TAGCCTGGTT -39,R5 9-GTGCTCCTTGCTTCACCTG -39
and probe 6 -FAM-AGTGACAGCCCTCAGCGACGAA-BBQ.
Addionally the PhHV isolation control was detected by using
primers F 59-TCCTGCTCCTTAGTAGCCTGGTT-39,R5 9-
GTGCTCCTTGCTTCACCTG -39 and probe 6 -FAM-AGTGA-
CAGCCCTCAGCGACGAA-BBQ. For the 28S detection a 8 fold
dilution series of the cloned PCR product was included to calculate
the number of copies per ml. The ratio of copies/ml and total DNA
isolated ng/ml was calculated to determine the Aspergillus sp. load of
each organ sample.
Statistics
Survival among groups was compared using Mann-Whitney
and Mantel-Cox tests. CFU-counts and quantitative PCR data
among the various treatment groups were compared using the
Mann-Whitney test.
Results
Strain identification and in vitro susceptibility
Following initial morphological identification, the A. fumigatus
species of the four isolateswas confirmed by sequence analysis of the
highly conserved b-tubulin gene. Microsatellite genotyping showed
that the four isolates were all STRAf type 3A: 48, 3B: 12, 3C: 15,
4A: 7, 4B: 8 and 4C: 10 and thus isogenic. The in vitro activity of
antifungal agents against the four isolates is shown in Table 1.
According to the recently proposed interpretative breakpoints
[25,26], isolate 1 and 2 were susceptible to itraconazole,
posaconazole and voriconazole, while isolates 3 and 4 were resistant
to these azoles. The antifungal activity of the polyenes and
echinocandins was not different for the four isolates (Table 1).
Development of secondary azole resistance following
prolonged antifungal drug exposure
The impact of the observed difference in vitro MICs was
investigated in an immunocompromised murine model of
disseminated aspergillosis. As the patient had been exposed to
azole monotherapy as well as to azole + echinocandin combina-
tion therapy, both regimens were investigated. Posaconazole
significantly improved survival, sterilised the kidneys and signifi-
cantly reduced the kidney Aspergillus DNA copy number in animals
challenged with susceptible isolate 2 when compared to untreated
animals (Fig. 1a–c). However, posaconazole failed to significantly
improve survival at the end of the study (Mann-Whitney P 0.0856)
(fig. 1d), reduce kidney CFU day 8 and 11 (fig. 1e) and kidney
Aspergillus copy number day 8 and 11 (fig. 1f) in animals challenged
with isolate 4 and all posaconazole treated animals were kidney
culture positive at all time points. In contrast, anidulafungin alone
or in combination with posaconazole significantly improved
survival (fig. 1d), significantly reduced kidney CFU day 4 and 8
(fig. 1e) and kidney Aspergillus copy number day 4, 8 and 11 for the
combination (fig. 1f) and anidulafungin alone or in combination
with posaconazole sterilised the kidneys in the majority of the
animals. The posaconazole resistance in isolate 4 was not absolute,
as significant kidney burden reduction was observed at the early
time point day 4 and mortality was delayed in posaconazole
treated animals (Mantel-Cox analysis P 0.0002) and as a tendency
was seen towards better efficacy in the combination group than in
the anidulafungin mono-therapy group.
Mechanism of resistance
As several substitutions in the cyp51A gene were reported to be
associated with an azole resistant phenotype [3,26], we sequenced
the coding Cyp51A gene together with the promoter region of this
gene of all four isolates to identify the presence of potential
mutations. Yet, the DNA sequencing results revealed no mutations
neither in the coding gene nor in its 59-upstream regulatory region.
This suggested that another yet unknown mechanism was
responsible for the change in azole activity.
In order to determine if the expression levels of the cyp51A was
altered, we performed real time PCR experiments comparing the
RNA expression levels of the four isolates and compared these to
the levels observed in a non-isogenic susceptible wild type strain
(AZN 8196), and a clinical CYP51A mutated isolate carrying the
TR/L98H substitution (Figure 2). A 4 to 6-fold induction of the
transcriptional profile of the resistant isolates 3 and 4 (0.2 (SEM
0.48) and 0.33 (SEM 0.11), respectively) compared to isolates 1
and 2 (1.4 (SEM 0.25) and 1.3 (SEM 0.52), respectively) and to the
reference wild-type (0.38 (SEM 0.51)) was found. This increased
level was half as high as the RNA expression level of the triazole
resistant isolate with the TR/L98H mutation and the 34 bp
tandem repeat in the Cyp51A-gene promoter (2.7 (SEM 1.4)).
Impact of resistance on virulence
The virulence of the four isolates was investigated in the mouse
model. As presented in Figure 3 there was a marked reduction of
virulence by the resistant isolates 3 and 4 compared to the
reference isolate, but also compared to the pre-treatment isolates 1
and 2 (Mantel-Cox test P values ranging between 0.0012 and
0.01). There was no significant difference in virulence between the
susceptible isolates 1 and 2 (Mantel-Cox test P=0.7) or between
the resistant isolates 3 and 4 (Mantel-Cox test P=0.29).
Further investigations focused on the morphology of the isolates
and the growth rates. Microscopic examinations of the conidia and
mycelia morphology of all 4 serial strains revealed no obvious
defects or changes. However, using in vitro growth analysis in
duplicates on agar plates, the resistant isolates 3 an 4 showed a
clear alteration in radial growth and a significantly reduced growth
rate compared to the reference isolate and compared to the
isolates 1 and 2 (Figure 4a). The kinetic evaluation of growth over
time in liquid RPMI medium supported this finding as the first
increase in optical density was delayed by 4 hours for isolates 3
and 4 and maximal growth was reduced compared with isolates 1
and 2 and the NCPF2109 control isolate (Figure 4b).
Discussion
For the first time we show that azole resistance may develop in
A. fumigatus during treatment of patients with CGD. As patients
Figure 1. In vivo susceptibility of sequential A. fumigatus isolates from a CGD patient failing azole therapy. Susceptibility is shown as
survival curve (a and d), as fungal CFU kidney burden (b and e) and as Aspergillus DNA load in kidney tissue. The early susceptible isolate (isolate no 2)
is shown in fig. a, b and c and the late resistant isolate (isolate no 4) in fig. c, d and e. AND: anidulafungin, POS: posaconazole, AND+POS: combination
therapy of anidulafungin and posaconazole, d4: day 4, d8: day 8, * P,0.05 compared to control.
doi:10.1371/journal.pone.0010080.g001
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time, sometimes life-long, this is an important and clinically
relevant observation. If A. fumigatus is cultured from CGD patients
during azole prophylaxis the in vitro susceptibility profile should
be determined. Selection of azole resistance during long term
treatment has been described previously [2,3,6,27], but in this case
emerged despite concomitant caspofungin treatment. This is
somewhat surprising as the sequential isolates were all in vitro
susceptible to caspofungin and anidulafungin, and echinocandin
susceptibility was confirmed in vivo in the mouse model. We have
previously described disseminated breakthrough A. fumigatus
infection following 40 days of caspofungin monotherapy in an
immunocompetent ICU patient with no predisposing pulmonary
disease [28]. These observations illustrate that in spite of low MEC
values the non-cidal anti-aspergillus activity of echinocandins may
not be sufficient to control aspergillus growth in vivo.
The set of isogenic isolates with different susceptibility profiles
offered a unique opportunity to investigate the characteristics of
resistance development in A. fumigatus. In clinical isolates azole
resistance has been associated with impaired interaction between
the drug and the target enzyme most commonly due to mutations
at one of the hot spot regions at codons 54, 98 and 220 in the
cyp51A gene [4,10,12,13,15,29–31]. Also alteration at codon 138
(G138C) or codon 448 (G to S) has been detected in clinical
isolates [2,32] and association with resistance confirmed using
laboratory generated mutants [33]. Finally, alterations at codons
216 (P to L), 431 (Y to C) and 434 (G to C) have recently been
demonstrated in azole resistant isolates with no other resistance
mutations but their association with resistance not yet experimen-
tally confirmed [3]. It is likely that numerous mechanisms and
target genes may be involved in development of azole resistance in
A. fumigatus, of which the Cyp51-gene is the first that was identified.
However, none of the above-mentioned mutations were found in
our isolates, but the reduced susceptibility to triazoles was found to
be associated with a 4–6 times increased cyp51A mRNA
expression. Increased expression of the Cyp51A gene is commonly
associated with the presence of transcriptional enhancers such as
tandem repeats in the gene promoter region. Tandem repeats
appear to be a common resistance mechanism in plant pathogenic
moulds [8]. In environmental non-Aspergillus moulds, significant
MIC increases of agricultural demethylase inhibitors have been
associated with increased cyp51A expression in isolates without
mutations in the target gene. A number of underlying mechanisms
have been demonstrated 1) a 126 bp tandem repeat in the
promoter region between nucleotide 2672 and 243 in Penicillium
digitatum leading to a 100 fold increase in expression level and with
a proportional relationship between number of repeats and
increase in MIC in laboratory generated mutants [34]; 2)
upstream insertion of various truncated derivatives of a long
interspersed nuclear element -like retrotransposon was detected in
all 59 examined demethylase resistant isolates of Blumeriella jaapii
[35], and 3) insertion of a unique 65 base pair repeat not normally
Figure 2. CYP51A mRNA levels in the 4 sequential A. fumigatus isolates and in a control wild type isolate AZN 8196 (WT) and a tri-
azole resistant control isolate with over-expression of the CYP51A gene due to the L98H mutation and promoter tandem repeat.
doi:10.1371/journal.pone.0010080.g002
Figure 3. In vivo virulence of sequential isolates of A. fumigatus
in immunosuppressed mice. Survival of mice in groups of six
challenged with each of the four sequential isolates (1–4) or a control
isolate (NCPF2109), respectively, is shown. The survival data was
combined per isolate, thus each survival curve displays the mortality of
six mice challenged with the indicated isolate, two of which were
challenged with a high inoculum (5x10
4 C F U / m l ) ,t w ow i t ha n
intermediate inoculum (10
4 CFU/ml) and two with a low inoculum
(2610
3 CFU/ml).
doi:10.1371/journal.pone.0010080.g003
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isolates of Monilinia fructicola suggesting it is a mobile genetic
element [36]. Finally, overexpression of the cyp51 gene due to
duplication of the entire chromosome containing the CYP51 gene
was observed in multi-azole resistant C. glabrata. A mechanism that
was lost over repeated passages in drug free medium [37]. It was
suggested that a tandem repeat may arise through sexual
reproduction of the fungus, while point mutations may be
associated with asexual reproduction [8]. Although we observed
an increased expression of the Cyp51A gene in the azole-resistant
isolates 3 and 4, compared to the isogenic isolates 1 and 2 with an
azole-susceptible phenotype, this was not associated with the
presence of a tandem repeat in the promoter region of the Cyp51A
gene. Furthermore, we previously observed that recombinants
with only the 34 bp tandem repeat showed increased expression of
the Cyp51A gene, but this did not correspond with the full azole-
resistant phenotype [15]. Only those isolates with the 34 bp
tandem repeat and the substitution at codon 98 exhibited the
multi-azole resistant phenotype [15]. Therefore, it remains unclear
if the increased expression observed in our isolates is the cause of
the resistant phenotype, although it may play a role. In order to
detect or rule out other resistance mechanisms full genome
sequencing of the susceptible and resistant isolates appears an
appropriate way forward. As there was a limited time interval
between culture of isolate 2 (azole-susceptible) and 3 (azole-
resistant), comparative genomics may reveal other, yet unknown,
resistance mechanisms.
The acquisition of azole resistance was associated with an
important change of the virulence of the resistant isolates. In our
murine model of invasive aspergillosis, the azole-resistant isolates
were less virulent than the isogenic azole-susceptible ones and the
wild-type controls. The in vivo virulence correlated with alteration
of the growth rate of the resistant isolates. If these isolates remain
capable of causing invasive disease is unclear although the
aspergillus disease was thought to have contributed to the death
of our patient and only resistant fungus was cultured from
respiratory samples shortly before his death. Although the
association between resistance and loss of fitness is well known
in various microorganisms, to our knowledge this is the first time
that it was observed in a human pathogenic mould. Loss of fitness
may be associated with the underlying resistance mechanism.
Preliminary experiments with A. fumigatus isolates with an azole-
resistant phenotype due to mutations in the Cyp51A-gene, suggest
that the virulence of these isolates is not reduced compared to
wild-type isolates [38].
To our best knowledge this is the first report describing
development of azole resistance during azole-echinocandin
combination therapy and to describe an impact of acquisition of
azole resistance on the virulence of the resistant isolates. A full
genome comparison of initial and late isolates is in process in order
to study the underlying mechanism in detail.
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Figure 4. Growth rate of the 4 sequential isolates expressed as radial growth rate on solid V8 agar (a) and as optical densities in
fluent medium (b). The laboratory strain NCP2109 is included as unrelated comparator. In the radial growth experiment (a) the growth rate is
expressed in mean diameter (mm) and Kr (mm/hour) after 24–72 hours of two separate experiments performed in triplicate. In the kinetic evaluation
of growth over time in liquid medium (b) growth is expressed as optical densities measured every 10 min.
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